Michael Barbella, Managing Editor07.26.23
HeartBeam Inc. has been granted a U.S. patent relating to the initial AI capability in the form of an expert system for its HeartBeam AIMIGoTM System. The patent is entitled, “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment.”
HeartBeam has developed the HeartBeam AIMIGo System, a personal, portable and easy-to-use VECG solution to help patients and clinicians assess cardiac symptoms. Its solution employs a reusable, credit card-sized, VECG recording device and cloud-based software to deliver critical data to clinicians in real-time outside of a medical setting. More than 127 million people in the United States have cardiovascular disease, including more than 20 million with coronary artery disease.
“We believe this patent will further our effort to create a dominant IP position in the area of ambulatory VECG. We believe that coupling AI with the highest resolution ambulatory ECG device available will have the power to deliver unprecedented diagnostic capability for patients experiencing acute cardiac symptoms, which will ultimately lead to improved care and saved lives,” HeartBeam Founder/CEO Branislav Vajdic, Ph.D., said. “This patent will be followed by an aggressive IP development effort with PatentVest as we refine our algorithms, systems and devices,” added Vajdic.
The newly allowed patent describes a system that combines the recorded cardiac signals from the HeartBeam AIMIGo VECG device with the patient’s symptoms and cardiac risk factors to calculate a cardiac risk score, providing simplified diagnostic information and actionable instructions to the patient. It aims to replicate the decision-making process a physician uses when assessing a patient with cardiac symptoms but performed remotely in an automated manner.
HeartBeam Inc. is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms.
HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (FDA) for marketing.
HeartBeam has developed the HeartBeam AIMIGo System, a personal, portable and easy-to-use VECG solution to help patients and clinicians assess cardiac symptoms. Its solution employs a reusable, credit card-sized, VECG recording device and cloud-based software to deliver critical data to clinicians in real-time outside of a medical setting. More than 127 million people in the United States have cardiovascular disease, including more than 20 million with coronary artery disease.
“We believe this patent will further our effort to create a dominant IP position in the area of ambulatory VECG. We believe that coupling AI with the highest resolution ambulatory ECG device available will have the power to deliver unprecedented diagnostic capability for patients experiencing acute cardiac symptoms, which will ultimately lead to improved care and saved lives,” HeartBeam Founder/CEO Branislav Vajdic, Ph.D., said. “This patent will be followed by an aggressive IP development effort with PatentVest as we refine our algorithms, systems and devices,” added Vajdic.
The newly allowed patent describes a system that combines the recorded cardiac signals from the HeartBeam AIMIGo VECG device with the patient’s symptoms and cardiac risk factors to calculate a cardiac risk score, providing simplified diagnostic information and actionable instructions to the patient. It aims to replicate the decision-making process a physician uses when assessing a patient with cardiac symptoms but performed remotely in an automated manner.
HeartBeam Inc. is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms.
HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (FDA) for marketing.